Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00609739 · OUTCOME

Patients With Regimen-Related Toxicity

Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation · Source last updated 2017-12-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Up to 30 Days Post Study Treatment

What was measured

Number of patients with adverse events related to treatment.

Groups in this outcome

Cytarabine + Mitoxantrone

Patients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cytarabine + Mitoxantrone1

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cytarabine + Mitoxantrone0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    units
    Participants
description
Number of patients with adverse events related to treatment.
groups
  1. description
    Patients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.
    id
    OG000
    title
    Cytarabine + Mitoxantrone
param Type
NUMBER
reporting Status
POSTED
time Frame
Up to 30 Days Post Study Treatment
title
Patients With Regimen-Related Toxicity
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice